Navigation Links
Sorrento Therapeutics' Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
Date:7/1/2011

SAN DIEGO, July 1, 2011 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) today announced that it has received an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded  in further support of the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus (S. aureus or "Staph") infections, including methicillin-resistant S. aureus (MRSA), by disrupting quorum sensing, a bacterial communication process essential to virulence. The Phase I grant award is for a total of $600,000, $300,000 annually for two years, with the possibility of Phase II funding of $1 million per year for up to 3 years. $300,000 was previously funded in 2010 and this second grant award represents year two of the Phase I grant award.  In recommending the grant application for funding, expert panel reviewers noted that targeting quorum sensing and the virulence factors of S. aureus represented a paradigm shift, which could result in fewer side effects than conventional drug therapies.

"In view of this second grant award, it is clear that the NIH remains highly motivated to fund the innovative approach of quorum quenching we licensed from The Scripps Research Institute (TSRI) to tackle the serious healthcare burden of Staph aureus infections," said Henry Ji, Ph.D., Interim Chief Executive Officer and Chief Scientific Officer of Sorrento Therapeutics.

Sorrento Therapeutics' MRSA program targets specific auto-inducing peptides (AIPs) central to the quorum sensing system of S. aureus, which induces bacterial virulence. Masking these AIPs leads to a disruption of bacterial communication ("quorum quenching") and suppresses virulence. In January of 2010,
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... free Importance of Mixing webinar will compare lab mixing and large ... Reinaldo M. Machado entitled "Fundamentals of Scale-up" and "iControl Mixing Guidelines". ... ... METTLER TOLEDO invites you to view a free on-demand webinar ...
... Cytopia Limited (ASX: CYT) announced that it will present ... at the forthcoming 100th Annual Meeting of the American ... David Segal, Principal Scientist at Cytopia, will be presenting ... Molecular Therapeutics 2 poster session on Tuesday, April ...
... China, April 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ... CSKI ), a,leading fully integrated pharmaceutical company producing ... announced that it will,conduct a conference call at 10:00 ... to discuss its fourth quarter and fiscal year 2008,financial ...
Cached Biology Technology:The Importance of Mixing: How to Compare Lab Scale Mixing with Full Scale Process Vessel Performance 2Cytopia Presentation on VDA CYT997 at AACR Conference 2China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Results 2
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/21/2014)... SAN JOSE, Calif. , Nov. 20, 2014 /PRNewswire/ ... a global leader in microcontroller (MCU) and touch technology ... digital temperature sensors with the widest V ... family delivers higher temperature accuracy and faster I 2 ... nonvolatile registers and serial EEPROM memory making them ideal ...
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... CSIRO researchers, in collaboration with the International Maize ... the research illustrates the major genetic improvements possible ... often use wild relatives of wheat as sources ... research team leader Dr Phil Larkin says. ...
... Growth hormone treatments work better on some children than on ... in height is no simple task. Now researchers have developed ... growth hormone to treat children who are abnormally short for ... the online open access journal BMC Medical Informatics and Decision ...
... the University of Southern California (USC) suggest epigenetics, or the ... cause for male infertility. The study will be published in ... This is the first report based on our ... semen development, says Rebecca Sokol, M.D., MPH, professor of obstetrics ...
Cached Biology News:Building disease-beating wheat 2USC researchers explore genetic causes for male infertility 2
... Nonanoyl-N-methylglucamide White ... Can be readily removed by dialysis. ... Purity: ≥98% by HPLC. Absorbance ... 2 O. CMC 19 - ...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
... polyclonal to HDAC4 - ChIP Grade ... II mammalian histone deacetylases, which consists of ... is highly similar to the deacetylase domain ... shuttles between the nucleus and cytoplasm in ...
Biology Products: